{"id":957653,"date":"2026-05-04T11:51:03","date_gmt":"2026-05-04T15:51:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/"},"modified":"2026-05-04T11:51:03","modified_gmt":"2026-05-04T15:51:03","slug":"esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/","title":{"rendered":"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR"},"content":{"rendered":"

<\/p>\n

\nEsperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR<\/p>\n

NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE<\/a>)–
\nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti<\/a>, LLC (\u201cKSF\u201d) are investigating the proposed sale of Esperion Therapeutics<\/a>, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.<\/p>\n

\n>>>CLICK HERE<\/a> To Learn More.<\/p>\n

\nIf you believe that this transaction undervalues the Company and\/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com<\/a>) toll free at any time at 855-768-1857, or visit https:\/\/www.ksfcounsel.com\/cases\/nasdaqgm-espr\/<\/a> to learn more.<\/p>\n

\nTo learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com<\/a>.<\/p>\n

\nCONNECT WITH US: Facebook<\/a> || Instagram<\/a> || YouTube<\/a> || TikTok<\/a> || LinkedIn<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260504965150\/en\/<\/a><\/span><\/p>\n

\nKahn Swick & Foti, LLC
\n
Managing Partner
\n
Lewis S. Kahn
\n
lewis.kahn@ksfcounsel.com
\n<\/a>
855-768-1857
\n
1100 Poydras St., Suite 960
\n
New Orleans, LA 70163<\/p>\n

KEYWORDS:<\/b> Louisiana New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)– Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or … <\/p>\n

Continue reading “Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957653","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEsperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)– Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or … Continue reading "Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T15:51:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR\",\"datePublished\":\"2026-05-04T15:51:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/\"},\"wordCount\":301,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/\",\"name\":\"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-05-04T15:51:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/","og_locale":"en_US","og_type":"article","og_title":"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR - Market Newsdesk","og_description":"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)– Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or … Continue reading \"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-04T15:51:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR","datePublished":"2026-05-04T15:51:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/"},"wordCount":301,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/","name":"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-05-04T15:51:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260504965150r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-therapeutics-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-esperion-therapeutics-inc-espr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. – ESPR"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957653"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957653\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}